SKYE Quote, Financials, Valuation and Earnings

FibroGen, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of -1221.75%. Skye Bioscience, Inc.'s return on equity of -91.57% beat FibroGen, Inc.'s return on equity of --.

Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 888.73%. On the other hand FibroGen, Inc. has an analysts' consensus of $43.00 which suggests that it could grow by 400.87%. Given that Skye Bioscience, Inc. has higher upside potential than FibroGen, Inc., analysts believe Skye Bioscience, Inc. is more attractive than FibroGen, Inc..

Skye Bioscience, Inc. has a beta of 2.676, which suggesting that the stock is 167.642% more volatile than S&P 500. In comparison FibroGen, Inc. has a beta of 0.747, suggesting its less volatile than the S&P 500 by 25.347%.

Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FibroGen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. FibroGen, Inc. pays out -- of its earnings as a dividend.

Skye Bioscience, Inc. quarterly revenues are --, which are smaller than FibroGen, Inc. quarterly revenues of $1.1M. Skye Bioscience, Inc.'s net income of -$12.8M is higher than FibroGen, Inc.'s net income of -$13.1M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while FibroGen, Inc.'s PE ratio is 0.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus 29.24x for FibroGen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of -36.3%. Skye Bioscience, Inc.'s return on equity of -91.57% beat Myomo, Inc.'s return on equity of -68.35%.

Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 888.73%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Skye Bioscience, Inc. has higher upside potential than Myomo, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Myomo, Inc..

Skye Bioscience, Inc. has a beta of 2.676, which suggesting that the stock is 167.642% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Skye Bioscience, Inc. quarterly revenues are --, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Skye Bioscience, Inc.'s net income of -$12.8M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theravance Biopharma, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of 18.08%. Skye Bioscience, Inc.'s return on equity of -91.57% beat Theravance Biopharma, Inc.'s return on equity of 14.9%.

Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 888.73%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 42.63%. Given that Skye Bioscience, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Theravance Biopharma, Inc..

Skye Bioscience, Inc. has a beta of 2.676, which suggesting that the stock is 167.642% more volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.143, suggesting its less volatile than the S&P 500 by 85.696%.

Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.

Skye Bioscience, Inc. quarterly revenues are --, which are smaller than Theravance Biopharma, Inc. quarterly revenues of $20M. Skye Bioscience, Inc.'s net income of -$12.8M is lower than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while Theravance Biopharma, Inc.'s PE ratio is 33.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus 11.75x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of --. Skye Bioscience, Inc.'s return on equity of -91.57% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 888.73%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 150.04%. Given that Skye Bioscience, Inc. has higher upside potential than Viking Therapeutics, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Viking Therapeutics, Inc..

Skye Bioscience, Inc. has a beta of 2.676, which suggesting that the stock is 167.642% more volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Skye Bioscience, Inc. quarterly revenues are --, which are smaller than Viking Therapeutics, Inc. quarterly revenues of --. Skye Bioscience, Inc.'s net income of -$12.8M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.